These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38372190)

  • 1. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network.
    Gandolfo P; Soeiro T; Jouve É; Revol B; Daveluy A; Bertin C; Eiden C; Gibaja V; Chaouachi L; Pérault-Pochat MC; Chevallier C; Aquizérate A; Le Boisselier R; Carton L; Lapeyre-Mestre M; Frauger É; Lacroix C; Micallef J
    Fundam Clin Pharmacol; 2024 Oct; 38(5):978-987. PubMed ID: 38372190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.
    Kwan ATH; Rosenblat JD; Mansur RB; Rhee TG; Teopiz K; Le GH; Wong S; Cao B; Ho R; McIntyre RS
    J Affect Disord; 2024 Oct; 363():589-594. PubMed ID: 39029700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Identification of abuse/dependence cases by the French addictovigilance network (FAN): A pilot study of the addictovigilance center and the psychotherapeutic center of Nancy (France)].
    Barberot P; Gibaja V; Benkhedda C; Dobre D; Tournebize J; Kahn JP
    Therapie; 2019 Jun; 74(3):389-397. PubMed ID: 30392700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Safety signal detection by the French Addictovigilance Network: Innovative methods of investigation, examples and usefulness for public health].
    Micallef J; Jouanjus É; Mallaret M; Lapeyre Mestre M
    Therapie; 2019 Dec; 74(6):579-590. PubMed ID: 31694770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Harm reduction centers ("CAARUD"): privileged places for warning signal detection in addictovigilance].
    Moracchini C; Frauger E; Pauly V; Nordmann S; Thirion X; Micallef J;
    Therapie; 2012; 67(5):437-45. PubMed ID: 23241253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data.
    Roussin A; Soeiro T; Fouque C; Jouanjus E; Frauger E; Fouilhé N; Mallaret M; Micallef J; Lapeyre-Mestre M;
    Br J Clin Pharmacol; 2022 Aug; 88(8):3789-3802. PubMed ID: 35318713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution.
    Dupui M; Micallef J; Lapeyre-Mestre M
    Therapie; 2019 Apr; 74(2):307-314. PubMed ID: 30798951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Twenty-five years of the French Addictovigilance Network (FAN)].
    Micallef J; Mallaret M
    Therapie; 2016 Sep; 71(4):375-8. PubMed ID: 27296806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal identification in addictovigilance: the functioning of the French system.
    Jouanjus E; Gibaja V; Kahn JP; Haramburu F; Daveluy A
    Therapie; 2015; 70(2):113-31. PubMed ID: 25858567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Surveillance system on drug abuse: Interest of the French national OPPIDUM program of French addictovigilance network].
    Frauger E; Pochard L; Boucherie Q; Giocanti A; Chevallier C; Daveluy A; Gibaja V; Caous AS; Eiden C; Authier N; Le Boisselier R; Guerlais M; Jouanjus É; Lepelley M; Pizzoglio V; Pain S; Richard N; Micallef J;
    Therapie; 2017 Sep; 72(4):491-501. PubMed ID: 28343650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM program.
    Lacroix C; Frauger E; Jouve E; Peyrière H; Micallef J
    Therapie; 2024 Oct; ():. PubMed ID: 39516089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022.
    Garnier C; Schein M; Lacroix C; Jouve E; Soeiro T; Gentile G; Lapeyre Mestre M; Micallef J
    CNS Drugs; 2024 Sep; 38(9):743-751. PubMed ID: 38990472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?
    Gentile G; Jego M; Spadari M; Griffiths K; Jouanjus E; Micallef J
    Fundam Clin Pharmacol; 2018 Dec; 32(6):643-651. PubMed ID: 30003596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detecting the diverted use of psychoactive drugs by adolescents and young adults: A pilot study.
    Jouanjus E; Falcou A; Deheul S; Roussin A; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1286-1292. PubMed ID: 30255533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of new psychoactive substances to mimic prescription drugs: The trend in France.
    Batisse A; Eiden C; Peyriere H; Djezzar S;
    Neurotoxicology; 2020 Jul; 79():20-24. PubMed ID: 32240674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Involvement of addictovigilance in emergency department for the detection of abuse and dependence cases: 3 years of experience].
    Serre A; Eiden C; Gourhant V; Laureau M; Perier D; Giraud I; Sebbane M; Peyrière H
    Therapie; 2018 Dec; 73(6):501-509. PubMed ID: 30017376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database.
    Bossard JB; Ponté C; Dupouy J; Lapeyre-Mestre M; Jouanjus E
    Clin Drug Investig; 2016 Sep; 36(9):735-742. PubMed ID: 27300651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Increase of overdose and deaths related to methadone during COVID-19 epidemic in 2020].
    Frauger E; Fouilhé N; Lacroix C; Daveluy A; Le Boisselier R; Bertin C; Revol B; Carton L; Chevalier C; Eiden C; Gibaja V; Aquizerate A; Chaouachi L; Bouquet E; Roussin A; Mallaret M; Micallef J
    Therapie; 2024; 79(3):297-306. PubMed ID: 37391322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health consequences of cocaine use in France: data from the French Addictovigilance Network.
    Eiden C; Vincent M; Serrand C; Serre A; Richard N; Picot MC; Frauger E; Fouilhé N; Daveluy A; Peyrière H;
    Fundam Clin Pharmacol; 2021 Apr; 35(2):455-465. PubMed ID: 32854152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018: Insights of the annual cross sectional OPPIDUM survey.
    Blayac L; Ponte C; Lavaud M; Micallef J; Lapeyre-Mestre M
    Therapie; 2023; 78(2):201-211. PubMed ID: 36283856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.